BLOOD PLASMA
Hemorrhagic Disease
University Health Network, Torontoother_biologicalPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Hemorrhagic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Damoctocog Alfa Pegol Bayer | Phase 4 | BBB |
Rivaroxaban Brigham and Women's Hospital | Phase 4 | BBB |
WARFARIN Asan Medical Center | Phase 4 | BBB |
ALTEPLASE Hamilton Health Sciences Corporation | Phase 4 | BB |
Pcc University Health Network, Toronto | Phase 4 | BB |
View all 24 →
Same molecule, other indications
BLOOD PLASMA is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →